G. Sathish Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
G. Sathish Kumar has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- M. Karthiga
Department of Computer Science and Engineering, Bannari Amman Institute of Technology, Erode, India
3 shared publications - P. Rajesh Kanna
Bannari Amman Institute of Technology
3 shared publications - G. Uma Maheshwari
Department of CSE (Artificial Intelligence and Machine Learning), Dr. Mahalingam College of Engineering and Technology, Coimbatore, India
2 shared publications - Mathappan Nivaashini
Sri Eshwar College of Engineering, India
2 shared publications - .H. Summia Parveen1 shared publication
- A. Andrine Dinola
P. A. College of Engineering and Technology (Autonomous)
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 6 (1) , 1643
Quantum-inspired context-aware adaptive federated edge intelligence for privacy-preserving healthcare analytics
- 25 October 2026
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 6 (1) , 1643
Open AccessQuantum-inspired context-aware adaptive federated edge intelligence for privacy-preserving healthcare analytics
- 16 October 2026
- Published by Springer Nature in International Journal of Machine Learning and Cybernetics
- Vol. 17 (11) , 502
Statistical and hybrid intelligent optimization approach for privacy preservation in IoT data
- 16 October 2026
- Published by Springer Nature in International Journal of Machine Learning and Cybernetics
- Vol. 17 (11) , 502
Statistical and hybrid intelligent optimization approach for privacy preservation in IoT data
- 30 September 2026
- Published by Springer Nature in Signal, Image and Video Processing
- Vol. 20 (13) , 672
Non-IID robust federated video anomaly detection with hybrid 3D CNN-transformer encoding and global differential privacy for multi-camera surveillance
- 30 September 2026
- Published by Springer Nature in Signal, Image and Video Processing
- Vol. 20 (13) , 672
Non-IID robust federated video anomaly detection with hybrid 3D CNN-transformer encoding and global differential privacy for multi-camera surveillance
- Open Access
- 29 June 2026
- Published by International Academic Institute for Science and Technology in International Academic Journal of Innovative Research
- Vol. 13 (2) , 42-49
Advances in Biotechnology for Developing Personalized Medicine Approaches in Clinical Practice
Personalized medicine has recently emerged as a revolutionary clinical paradigm that enables individualized disease prevention, diagnosis, and treatment guided by a patient's genetic, molecular, and clinical factors. While much progress has been made in applying biotechnology to realize the goals of personalized care, issues of inter-patient heterogeneity, the time lag in biomarker discovery, and the inadequacies of existing one-size-fits-all medical paradigms still undermine clinical benefit. In this study, we have examined current advances in applying biotechnology to developing clinical approaches for personalized medicine. This process integrates genomic profiling, molecular diagnostics, biomarker identification, patient stratification, and treatment selection into a single framework. We utilized 520 patient profiles from categories spanning oncology, cardiovascular diseases, neurological disorders, metabolic syndromes, and inherited diseases, and applied a structured analysis approach. Comparing the diagnostic effectiveness of the developed framework with a standard clinical protocol for disease intervention in a clinical evaluation study showed that the classification accuracy, sensitivity, and specificity of the patient characterization protocol within the biotechnology-driven framework were 94.6%, 91.8%, and 93.4%, respectively. The treatment recommendation model developed using the biomarker discovery framework achieved a drug-matching rate of 93.2%, while 87.5% of patient populations achieved clinical efficacy post-biomarker-directed therapeutic intervention. In addition, improvements of 18.7%, 16.4%, and 24.5%, and a reduction of 21.3% were observed in diagnostic accuracy, drug treatment selection efficiency, clinical treatment efficacy, and adverse drug reactions, respectively, compared with conventional clinical protocols. Our study suggests that integrating genetics and molecular analytics into precision medicine contributes to more precise diagnoses, more precise treatment decisions, and more effective therapy selection for individual patients, and will help realize its large-scale implementation as part of the next generation of clinical systems.
- 29 June 2026
- Published by International Academic Institute for Science and Technology in International Academic Journal of Innovative Research
- Vol. 13 (2) , 42-49
Open AccessAdvances in Biotechnology for Developing Personalized Medicine Approaches in Clinical Practice
Personalized medicine has recently emerged as a revolutionary clinical paradigm that enables individualized disease prevention, diagnosis, and treatment guided by a patient's genetic, molecular, and clinical factors. While much progress has been made in applying biotechnology to realize the goals of personalized care, issues of inter-patient heterogeneity, the time lag in biomarker discovery, and the inadequacies of existing one-size-fits-all medical paradigms still undermine clinical benefit. In this study, we have examined current advances in applying biotechnology to developing clinical approaches for personalized medicine. This process integrates genomic profiling, molecular diagnostics, biomarker identification, patient stratification, and treatment selection into a single framework. We utilized 520 patient profiles from categories spanning oncology, cardiovascular diseases, neurological disorders, metabolic syndromes, and inherited diseases, and applied a structured analysis approach. Comparing the diagnostic effectiveness of the developed framework with a standard clinical protocol for disease intervention in a clinical evaluation study showed that the classification accuracy, sensitivity, and specificity of the patient characterization protocol within the biotechnology-driven framework were 94.6%, 91.8%, and 93.4%, respectively. The treatment recommendation model developed using the biomarker discovery framework achieved a drug-matching rate of 93.2%, while 87.5% of patient populations achieved clinical efficacy post-biomarker-directed therapeutic intervention. In addition, improvements of 18.7%, 16.4%, and 24.5%, and a reduction of 21.3% were observed in diagnostic accuracy, drug treatment selection efficiency, clinical treatment efficacy, and adverse drug reactions, respectively, compared with conventional clinical protocols. Our study suggests that integrating genetics and molecular analytics into precision medicine contributes to more precise diagnoses, more precise treatment decisions, and more effective therapy selection for individual patients, and will help realize its large-scale implementation as part of the next generation of clinical systems.
- 21 February 2026
- Published by Springer Nature
- p. 1-10
The Urgency of Change: Climate and Environmental Challenges in the Quantum Era
- 21 February 2026
- Published by Springer Nature
- p. 1-10
The Urgency of Change: Climate and Environmental Challenges in the Quantum Era
- Open Access
- 4 February 2026
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 6 (1)
An effective ECOLASSO with black widow optimization for feature selection and stagewise adaptive learning rate for disease prediction
Machine learning techniques are utilized for early detection of diseases, which can significantly enhance probabilities of positive treatment and existence. The traditional machine learning algorithms may be unable to predict outcomes with sufficient accuracy. In this work, an Effective ECOLASSO with Black Widow Optimization for Feature Selection and Stagewise Adaptive Learning Rate (ELBWOSALR) classifier is proposed for feature selection and prediction. The proposed work comprises two phases, in the first phase, Ecological similarity Least Absolute Shrinkage and Selection Operator (ECOLASSO) model is utilized to predict the best features from the dataset by removing the feature with smallest absolute regression coefficient from the feature set. A Black Widow Optimizer (BWO) is used to choose the subset of optimal features and to reduce local optima. In the second phase, Stagewise Adaptive Learning Rate (SALR) involves combining several weak learner classifiers into a strong ensemble classifier by adaptive learning rate. The key contribution of this work is the integration of ECOLASSO model with BWO for robust feature selection, combined with a SALR classifier. This hybridization addresses two critical challenges simultaneously: (i) ECOLASSO ensures sparsity and ecological similarity-driven selection of relevant features, while (ii) BWO prevents premature convergence and enhances global search efficiency. By coupling these with SALR, our model achieves superior accuracy and generalization compared to conventional classifiers. Lung cancer, breast cancer and heart disease datasets are used for experimentation. The ELBWOSALR classifier is compared with various classifier models such as Support Vector Classifier, Decision Tree Classifier, Random Forest Classifier, Logistic Regression, Extreme Gradient Boost Classifier, Gradient Boosting Classifier, K-Nearest Neighbors Classifier and CatBoost Classifier and the results are observed. The proposed ELBWOSALR classifier achieves accuracies of 98%, 97% and 91% with AUC values of 92%, 99% and 94% for lung cancer, breast cancer and heart disease datasets respectively.
- 4 February 2026
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 6 (1)
Open AccessAn effective ECOLASSO with black widow optimization for feature selection and stagewise adaptive learning rate for disease prediction
Machine learning techniques are utilized for early detection of diseases, which can significantly enhance probabilities of positive treatment and existence. The traditional machine learning algorithms may be unable to predict outcomes with sufficient accuracy. In this work, an Effective ECOLASSO with Black Widow Optimization for Feature Selection and Stagewise Adaptive Learning Rate (ELBWOSALR) classifier is proposed for feature selection and prediction. The proposed work comprises two phases, in the first phase, Ecological similarity Least Absolute Shrinkage and Selection Operator (ECOLASSO) model is utilized to predict the best features from the dataset by removing the feature with smallest absolute regression coefficient from the feature set. A Black Widow Optimizer (BWO) is used to choose the subset of optimal features and to reduce local optima. In the second phase, Stagewise Adaptive Learning Rate (SALR) involves combining several weak learner classifiers into a strong ensemble classifier by adaptive learning rate. The key contribution of this work is the integration of ECOLASSO model with BWO for robust feature selection, combined with a SALR classifier. This hybridization addresses two critical challenges simultaneously: (i) ECOLASSO ensures sparsity and ecological similarity-driven selection of relevant features, while (ii) BWO prevents premature convergence and enhances global search efficiency. By coupling these with SALR, our model achieves superior accuracy and generalization compared to conventional classifiers. Lung cancer, breast cancer and heart disease datasets are used for experimentation. The ELBWOSALR classifier is compared with various classifier models such as Support Vector Classifier, Decision Tree Classifier, Random Forest Classifier, Logistic Regression, Extreme Gradient Boost Classifier, Gradient Boosting Classifier, K-Nearest Neighbors Classifier and CatBoost Classifier and the results are observed. The proposed ELBWOSALR classifier achieves accuracies of 98%, 97% and 91% with AUC values of 92%, 99% and 94% for lung cancer, breast cancer and heart disease datasets respectively.
- 21 August 2025
- Published by Springer Nature
- p. 91-101
Herbal Detector: Advancing Medicinal Plant Recognition Using CNN and Pixel-Based Evaluations
- 21 August 2025
- Published by Springer Nature
- p. 91-101
Herbal Detector: Advancing Medicinal Plant Recognition Using CNN and Pixel-Based Evaluations
- 15 July 2025
- Published by Springer Nature
- p. 419-429
Efficient Deep Learning-Based Approaches for Early Diagnosis of Diabetes Mellitus
- 15 July 2025
- Published by Springer Nature
- p. 419-429
Efficient Deep Learning-Based Approaches for Early Diagnosis of Diabetes Mellitus
- Open Access
- 24 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (13) , 1339
Gene-Based Predictive Modelling for Enhanced Detection of Systemic Lupus Erythematosus Using CNN-Based DL Algorithm
Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disease that presents with a diverse array of clinical signs and unpredictable disease progression. Conventional diagnostic methods frequently fall short in terms of sensitivity and specificity, which can result in delayed diagnosis and less-than-optimal management. In this study, we introduce a novel approach for improving the identification of SLE through the use of gene-based predictive modelling and Stacked deep learning classifiers. The study proposes a new method for diagnosing SLE using Stacked Deep Learning Classifiers (SDLC) trained on Gene Expression Omnibus (GEO) database data. By combining transcriptomic data from GEO with clinical features and laboratory results, the SDLC model achieves a remarkable accuracy value of 0.996, outperforming traditional methods. Individual models within the SDLC, such as SBi-LSTM and ACNN, achieved accuracies of 92% and 95%, respectively. The SDLC’s ensemble learning approach allows for identifying complex patterns in multi-modal data, enhancing accuracy in diagnosing SLE. This study emphasises the potential of deep learning methods, in conjunction with open repositories like GEO, to advance the diagnosis and management of SLE. Overall, this research shows strong performance and potential for improving precision medicine in managing SLE.
- 24 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (13) , 1339
Open AccessGene-Based Predictive Modelling for Enhanced Detection of Systemic Lupus Erythematosus Using CNN-Based DL Algorithm
Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disease that presents with a diverse array of clinical signs and unpredictable disease progression. Conventional diagnostic methods frequently fall short in terms of sensitivity and specificity, which can result in delayed diagnosis and less-than-optimal management. In this study, we introduce a novel approach for improving the identification of SLE through the use of gene-based predictive modelling and Stacked deep learning classifiers. The study proposes a new method for diagnosing SLE using Stacked Deep Learning Classifiers (SDLC) trained on Gene Expression Omnibus (GEO) database data. By combining transcriptomic data from GEO with clinical features and laboratory results, the SDLC model achieves a remarkable accuracy value of 0.996, outperforming traditional methods. Individual models within the SDLC, such as SBi-LSTM and ACNN, achieved accuracies of 92% and 95%, respectively. The SDLC’s ensemble learning approach allows for identifying complex patterns in multi-modal data, enhancing accuracy in diagnosing SLE. This study emphasises the potential of deep learning methods, in conjunction with open repositories like GEO, to advance the diagnosis and management of SLE. Overall, this research shows strong performance and potential for improving precision medicine in managing SLE.